<DOC>
	<DOCNO>NCT00536575</DOCNO>
	<brief_summary>This single-arm Phase I/II study sorafenib bortezomib dose optimization initial patient . The initial patient dose-finding portion study enrol single institution . Following establishment Phase II dose study open enrollment throughout Sarah Cannon Research Institute ( SCRI ) Oncology Research Consortium . The purpose study develop combination bortezomib ( prove clinically active patient multiple myeloma ) sorafenib ( potent inhibitor angiogenesis ) . This regimen develop schedule convenient patient , minimally toxic patient possible .</brief_summary>
	<brief_title>Sorafenib Bortezomib Treatment Relapsed Refractory Multiple Myeloma Patients</brief_title>
	<detailed_description>Primary Objective : To evaluate efficacy sorafenib weekly bortezomib , measure objective response rate progression-free survival patient relapsed/refractory multiple myeloma . Secondary Objective : To evaluate feasibility toxicity sorafenib weekly bortezomib treatment patient relapsed/refractory multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Eligible participant must previously diagnose use standard criterion receive 2 prior regimen treatment multiple myeloma . Participant must define Relapsed Refractory Disease one follow criterion prior enrollment : Relapsed Disease highdose therapy ( autologous stem cell transplantation ) part firstline line treatment program . These patient may receive maximum 1 previous regimen , Refractory Disease Relapsed Disease &gt; 1 prior therapy multiple myeloma . Prior bortezomib treatment permit patient achieve documented response . ECOG performance status 0 , 1 , 2 . WBC &gt; = 3000 ; ANC &gt; = 1000 ; platelet &gt; = 50,000 ( Patients platelet &gt; = 30,000 eligible thrombocytopenia felt due extensive bone marrow involvement myeloma ) . Serum creatinine &lt; 2.0 mg/dL calculate measured creatinine clearance &gt; 30 mL/minute Total bilirubin &lt; 1.5 x ULN ALT AST &lt; 2.5 x ULN ( &lt; 5 x ULN patient liver involvement ) INR &lt; 1.5 PT/PTT within normal limit . Patients receive anticoagulation treatment agent warfarin heparin may allow participate . For patient warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . Patients must measurable evaluable disease . In patient disease limit bone bone marrow , serial paraprotein measurement acceptable evaluable disease . Patients &gt; grade 1 peripheral neuropathy . Thrombolic embolic event cerebrovascular accident , include transient ischemic attack , within past 6 month . Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug . Known brain metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . Patients medical condition would potentially interfere participation trial . Patients active malignancy , history treatment invasive cancer , within 3 year study entry . Patients previous evidence hypersensitivity sorafenib , bortezomib , boron , mannitol . Women pregnant lactate ineligible . All patient childbearing potential require use adequate method contraception receive study treatment , least 2 week last dose sorafenib . Men continue use contraception least 3 month last dose sorafenib . Evidence POEMS ( polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ) syndrome . Cardiac disease : Congestive heart failure &gt; class II NYHA ( see Appendix D. ) Patients must unstable angina ( anginal symptom rest ) , new onset angina ( begin within last 3 month ) , myocardial infarction within past 6 month . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. Active clinically serious infection &gt; CTCAE Grade 2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Bortezomib</keyword>
</DOC>